{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T03:42:57Z","timestamp":1785555777396,"version":"3.56.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T00:00:00Z","timestamp":1664236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T00:00:00Z","timestamp":1664236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["NUM-COVID 19 \u2013 Organo-Strat 01KX2021"],"award-info":[{"award-number":["NUM-COVID 19 \u2013 Organo-Strat 01KX2021"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"name":"German myasthenia gravis Society"},{"DOI":"10.13039\/100006396","name":"Alexion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006188","name":"Einstein Stiftung Berlin","doi-asserted-by":"publisher","award":["16GW0191"],"award-info":[{"award-number":["16GW0191"]}],"id":[{"id":"10.13039\/501100006188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Patients with myasthenia gravis (MG) are potentially prone for a severe COVID-19 course, but there are limited real-world data available on the risk associated with COVID-19 for patients with MG. Here, we investigate whether current immunosuppressive therapy (IST) influences the risk of SARS-CoV-2 infection and COVID-19 severity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Data from the German myasthenia gravis registry were analyzed from May 2020 until June 2021 and included patient demographics, MG disease duration, comorbidities, current IST use, COVID-19 characteristics, and outcomes. Propensity score matching was employed to match MG patients with IST to those without, and multivariable binary logistic regression models were used to determine associations between IST with (1) symptomatic SARS-CoV-2 infection and (2) severe COVID-19 course, as measured by hospitalization or death.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of 1379 patients with MG, 95 (7%) patients (mean age 58 (standard deviation [SD] 18) presented with COVID-19, of which 76 (80%) received IST at time of infection. 32 patients (34%) were hospitalized due to COVID-19; a total of 11 patients (12%) died. IST was a risk factor for hospitalization or death in the group of COVID-19-affected MG patients (odds ratio [OR] 3.04, 95% confidence interval [CI]\u2009=\u20091.02\u20139.06, <jats:italic>p<\/jats:italic>\u2009=\u20090.046), but current IST was not associated with a higher risk for SARS-CoV-2 infection itself.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>In this national MG cohort study, current IST use was a risk factor for a severe disease course of COVID-19 but not for SARS-CoV-2 infection itself. These data support the consequent implementation of effective strategies to prevent COVID-19 in this high-risk group.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration information<\/jats:title>\n                <jats:p>German clinical trial registry (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.drks.de\">https:\/\/www.drks.de<\/jats:ext-link>), DRKS00024099, first patient enrolled: February 4th, 2019.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00415-022-11389-0","type":"journal-article","created":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T04:02:32Z","timestamp":1664251352000},"page":"1-12","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Risk and course of COVID-19 in immunosuppressed patients with myasthenia gravis"],"prefix":"10.1007","volume":"270","clinical-trial-number":[{"clinical-trial-number":"drks00024099","registry":"10.18810\/drks"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5306-7880","authenticated-orcid":false,"given":"Frauke","family":"Stascheit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Grittner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Mergenthaler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schroeter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Ruck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Pawlitzki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz","family":"Blaes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Schara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adela","family":"Della-Marina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Thieme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Hagenacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Jacobi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter P.","family":"Urban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl Christian","family":"Knop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berthold","family":"Schalke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De-Hyung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Kalischewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Wiendl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Meisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,27]]},"reference":[{"key":"11389_CR1","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2022.107140","volume":"213","author":"AS Abbas","year":"2022","unstructured":"Abbas AS, Hardy N, Ghozy S, Dibas M, Paranjape G, Evanson KW, Reierson NL, Cowie K, Kamrowski S, Schmidt S, Tang Y, Davis AR, Touchette JC, Kallmes KM, Hassan AE, Tarchand R, Mehta M, Pederson JM, Abdelmegeed M (2022) Characteristics, treatment, and outcomes of Myasthenia Gravis in COVID-19 patients: a systematic review. Clin Neurol Neurosurg 213:107140","journal-title":"Clin Neurol Neurosurg"},{"key":"11389_CR2","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/mus.26918","volume":"62","author":"P Anand","year":"2020","unstructured":"Anand P, Slama MCC, Kaku M, Ong C, Cervantes-Arslanian AM, Zhou L, David WS, Guidon AC (2020) COVID-19 in patients with myasthenia gravis. Muscle Nerve 62:254\u2013258","journal-title":"Muscle Nerve"},{"key":"11389_CR3","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100590","volume":"28","author":"D Annane","year":"2020","unstructured":"Annane D, Heming N, Grimaldi-Bensouda L, Fr\u00e9meaux-Bacchi V, Vigan M, Roux AL, Marchal A, Michelon H, Rottman M, Moine P (2020) Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: a proof-of-concept study. EClinicalMedicine 28:100590","journal-title":"EClinicalMedicine"},{"key":"11389_CR4","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/pst.433","volume":"10","author":"PC Austin","year":"2011","unstructured":"Austin PC (2011) Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat 10:150\u2013161","journal-title":"Pharm Stat"},{"issue":"6","key":"11389_CR5","doi-asserted-by":"publisher","first-page":"e419","DOI":"10.1016\/S2665-9913(21)00059-X","volume":"3","author":"J Avouac","year":"2021","unstructured":"Avouac J, Drumez E, Hachulla E, Seror R, Georgin-Lavialle S, El Mahou S, Pertuiset E, Pham T, Marotte H, Servettaz A, Domont F, Chazerain P, Devaux M, Claudepierre P, Langlois V, Mekinian A, Maria ATJ, Banneville B, Fautrel B, Pouchot J, Thomas T, Flipo RM, Richez C (2021) COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study. Lancet Rheumatol 3(6):e419\u2013e426. https:\/\/doi.org\/10.1016\/S2665-9913(21)00059-X","journal-title":"Lancet Rheumatol"},{"key":"11389_CR6","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/mus.27324","volume":"64","author":"P Businaro","year":"2021","unstructured":"Businaro P, Vaghi G, Marchioni E, Diamanti L, Arceri S, Bini P, Colombo E, Cosentino G, Alfonsi E, Costa A, Ravaglia S, Mallucci G, Ballante E, Franciotta D, Gastaldi M (2021) COVID-19 in patients with myasthenia gravis: epidemiology and disease course. Muscle Nerve 64:206\u2013211","journal-title":"Muscle Nerve"},{"key":"11389_CR7","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1038\/s41590-020-0779-1","volume":"21","author":"M Buszko","year":"2020","unstructured":"Buszko M, Park JH, Verthelyi D, Sen R, Young HA, Rosenberg AS (2020) The dynamic changes in cytokine responses in COVID-19: a snapshot of the current state of knowledge. Nat Immunol 21:1146\u20131151","journal-title":"Nat Immunol"},{"key":"11389_CR8","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.3389\/fneur.2020.01053","volume":"11","author":"AE Camelo-Filho","year":"2020","unstructured":"Camelo-Filho AE, Silva AMS, Estephan EP, Zambon AA, Mendon\u00e7a RH, Souza PVS, Pinto W, Oliveira ASB, Dangoni-Filho I, Pouza AFP, Valerio BCO, Zanoteli E (2020) Myasthenia Gravis and COVID-19: clinical characteristics and outcomes. Front Neurol 11:1053","journal-title":"Front Neurol"},{"key":"11389_CR9","first-page":"4040","volume":"24","author":"F Diurno","year":"2020","unstructured":"Diurno F, Numis FG, Porta G, Cirillo F, Maddaluno S, Ragozzino A, De Negri P, Di Gennaro C, Pagano A, Allegorico E, Bressy L, Bosso G, Ferrara A, Serra C, Montisci A, D\u2019Amico M, Schiano Lo Morello S, Di Costanzo G, Tucci AG, Marchetti P, Di Vincenzo U, Sorrentino I, Casciotta A, Fusco M, Buonerba C, Berretta M, Ceccarelli M, Nunnari G, Diessa Y, Cicala S, Facchini G (2020) Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience. Eur Rev Med Pharmacol Sci 24:4040\u20134047","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"11389_CR10","first-page":"Cd002277","volume":"12","author":"P Gajdos","year":"2012","unstructured":"Gajdos P, Chevret S, Toyka KV (2012) Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev 12:Cd002277","journal-title":"Cochrane Database Syst Rev"},{"key":"11389_CR11","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/all.14657","volume":"76","author":"YD Gao","year":"2021","unstructured":"Gao YD, Ding M, Dong X, Zhang JJ, Kursat Azkur A, Azkur D, Gan H, Sun YL, Fu W, Li W, Liang HL, Cao YY, Yan Q, Cao C, Gao HY, Br\u00fcggen MC, van de Veen W, Sokolowska M, Akdis M, Akdis CA (2021) Risk factors for severe and critically ill COVID-19 patients: a review. Allergy 76:428\u2013455","journal-title":"Allergy"},{"key":"11389_CR12","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s10238-020-00671-y","volume":"21","author":"M Gavriatopoulou","year":"2021","unstructured":"Gavriatopoulou M, Ntanasis-Stathopoulos I, Korompoki E, Fotiou D, Migkou M, Tzanninis IG, Psaltopoulou T, Kastritis E, Terpos E, Dimopoulos MA (2021) Emerging treatment strategies for COVID-19 infection. Clin Exp Med 21:167\u2013179","journal-title":"Clin Exp Med"},{"key":"11389_CR13","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/annrheumdis-2020-217871","volume":"79","author":"M Gianfrancesco","year":"2020","unstructured":"Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI, Gossec L, Izadi Z, Jacobsohn L, Katz P, Lawson-Tovey S, Mateus EF, Rush S, Schmajuk G, Simard J, Strangfeld A, Trupin L, Wysham KD, Bhana S, Costello W, Grainger R, Hausmann JS, Liew JW, Sirotich E, Sufka P, Wallace ZS, Yazdany J, Machado PM, Robinson PC (2020) Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 79:859\u2013866","journal-title":"Ann Rheum Dis"},{"key":"11389_CR14","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1056\/NEJMra1602678","volume":"375","author":"NE Gilhus","year":"2016","unstructured":"Gilhus NE (2016) Myasthenia Gravis. N Engl J Med 375:2570\u20132581","journal-title":"N Engl J Med"},{"key":"11389_CR15","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1001\/jamainternmed.2020.3539","volume":"180","author":"G Grasselli","year":"2020","unstructured":"Grasselli G, Greco M, Zanella A, Albano G, Antonelli M, Bellani G, Bonanomi E, Cabrini L, Carlesso E, Castelli G, Cattaneo S, Cereda D, Colombo S, Coluccello A, Crescini G, Forastieri Molinari A, Foti G, Fumagalli R, Iotti GA, Langer T, Latronico N, Lorini FL, Mojoli F, Natalini G, Pessina CM, Ranieri VM, Rech R, Scudeller L, Rosano A, Storti E, Thompson BT, Tirani M, Villani PG, Pesenti A, Cecconi M (2020) Risk factors associated with mortality among patients with COVID-19 in Intensive Care Units in Lombardy, Italy. JAMA Intern Med 180:1345\u20131355","journal-title":"JAMA Intern Med"},{"key":"11389_CR16","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/mus.26689","volume":"60","author":"RR Gummi","year":"2019","unstructured":"Gummi RR, Kukulka NA, Deroche CB, Govindarajan R (2019) Factors associated with acute exacerbations of myasthenia gravis. Muscle Nerve 60:693\u2013699","journal-title":"Muscle Nerve"},{"key":"11389_CR17","doi-asserted-by":"publisher","first-page":"e001464","DOI":"10.1136\/rmdopen-2020-001464","volume":"7","author":"R Hasseli","year":"2021","unstructured":"Hasseli R, Mueller-Ladner U, Hoyer BF, Krause A, Lorenz HM, Pfeil A, Richter J, Sch\u00e4fer M, Schmeiser T, Strangfeld A, Schulze-Koops H, Voll RE, Specker C, Regierer AC (2021) Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases. RMD Open 7:e001464. https:\/\/doi.org\/10.1136\/rmdopen-2020-001464","journal-title":"RMD Open"},{"issue":"8","key":"11389_CR18","first-page":"2011","volume":"1","author":"D Ho","year":"2011","unstructured":"Ho D, Imai K, King G, Stuart EA (2011) MatchIt: nonparametric preprocessing for parametric causal inference. J Stat Softw 1(8):2011","journal-title":"J Stat Softw"},{"issue":"2","key":"11389_CR19","first-page":"2006","volume":"1","author":"S H\u00f8jsgaard","year":"2005","unstructured":"H\u00f8jsgaard S, Halekoh U, Yan J (2005) The R Package geepack for generalized estimating equations. J Stat Softw 1(2):2006","journal-title":"J Stat Softw"},{"key":"11389_CR20","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","volume":"384","author":"P Horby","year":"2021","unstructured":"Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Montgomery A, Rowan K, Juszczak E, Baillie JK, Haynes R, Landray MJ (2021) Dexamethasone in hospitalized patients with COVID-19. N Engl J Med 384:693\u2013704","journal-title":"N Engl J Med"},{"key":"11389_CR21","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","volume":"16","author":"JF Howard Jr","year":"2017","unstructured":"Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Muppidi S, Nowak RJ, O\u2019Brien F, Wang JJ, Mantegazza R (2017) Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol 16:976\u2013986","journal-title":"Lancet Neurol"},{"key":"11389_CR22","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395:497\u2013506","journal-title":"Lancet"},{"key":"11389_CR23","volume":"12","author":"TS Ipe","year":"2021","unstructured":"Ipe TS, Davis AR, Raval JS (2021) Therapeutic plasma exchange in myasthenia gravis: a systematic literature review and meta-analysis of comparative evidence. Front Neurol 12:662856","journal-title":"Front Neurol"},{"key":"11389_CR24","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2020.116803","volume":"412","author":"S Jacob","year":"2020","unstructured":"Jacob S, Muppidi S, Guidon A, Guptill J, Hehir M, Howard JF Jr, Illa I, Mantegazza R, Murai H, Utsugisawa K, Vissing J, Wiendl H, Nowak RJ (2020) Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic. J Neurol Sci 412:116803","journal-title":"J Neurol Sci"},{"issue":"10","key":"11389_CR25","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.1111\/ene.14951","volume":"28","author":"M Jakub\u00edkov\u00e1","year":"2021","unstructured":"Jakub\u00edkov\u00e1 M, T\u00fdblov\u00e1 M, Tesa\u0159 A, Hor\u00e1kov\u00e1 M, Vla\u017en\u00e1 D, Ry\u0161\u00e1nkov\u00e1 I, Nov\u00e1kov\u00e1 I, Dole\u010dkov\u00e1 K, Du\u0161ek P, Pi\u0165ha J, Voh\u00e1\u0148ka S, Bedna\u0159\u00edk J (2021) Predictive factors for a severe course of COVID-19 infection in myasthenia gravis patients with an overall impact on myasthenic outcome status and survival. Eur J Neurol 28(10):3418\u20133425. https:\/\/doi.org\/10.1111\/ene.14951 (Erratum in: Eur J Neurol. 2022 Feb;29(2):682. PMID: 34080271; PMCID: PMC8239548)","journal-title":"Eur J Neurol"},{"key":"11389_CR26","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2021.106488","volume":"202","author":"J Kalita","year":"2021","unstructured":"Kalita J, Tripathi A, Dongre N, Misra UK (2021) Impact of COVID-19 pandemic and lockdown in a cohort of myasthenia gravis patients in India. Clin Neurol Neurosurg 202:106488","journal-title":"Clin Neurol Neurosurg"},{"key":"11389_CR27","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1053\/j.ajkd.2008.02.360","volume":"52","author":"AA Kaplan","year":"2008","unstructured":"Kaplan AA (2008) Therapeutic plasma exchange: core curriculum 2008. Am J Kidney Dis 52:1180\u20131196","journal-title":"Am J Kidney Dis"},{"key":"11389_CR28","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/ene.14153","volume":"27","author":"CD Kassardjian","year":"2020","unstructured":"Kassardjian CD, Widdifield J, Paterson JM, Kopp A, Nagamuthu C, Barnett C, Tu K, Breiner A (2020) Serious infections in patients with myasthenia gravis: population-based cohort study. Eur J Neurol 27:702\u2013708","journal-title":"Eur J Neurol"},{"issue":"8","key":"11389_CR29","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.3390\/v13081484","volume":"13","author":"\u0141J Krzych","year":"2021","unstructured":"Krzych \u0141J, Putowski Z, Czok M, Hofman M (2021) What is the role of therapeutic plasma exchange as an adjunctive treatment in severe COVID-19: a systematic review. Viruses 13(8):1484","journal-title":"Viruses"},{"issue":"6","key":"11389_CR30","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1007\/s00415-021-10891-1","volume":"269","author":"S Lehnerer","year":"2021","unstructured":"Lehnerer S, Jacobi J, Schilling R, Grittner U, Marbin D, Gerischer L, Stascheit F, Krause M, Hoffmann S, Meisel A (2021) Burden of disease in myasthenia gravis: taking the patient\u2019s perspective. J Neurol 269(6):3050\u20133063","journal-title":"J Neurol"},{"key":"11389_CR31","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/mus.27130","volume":"63","author":"Y Li","year":"2021","unstructured":"Li Y, Emmett CD, Cobbaert M, Sanders DB, Juel VC, Hobson-Webb LD, Massey JM, Gable KL, Raja SM, Gonzalez NL, Guptill JT (2021) Knowledge and perceptions of the COVID-19 pandemic among patients with myasthenia gravis. Muscle Nerve 63:357\u2013364","journal-title":"Muscle Nerve"},{"key":"11389_CR32","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","volume":"77","author":"G Luna","year":"2020","unstructured":"Luna G, Alping P, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, Hillert J, Langer-Gould A, Lycke J, Nilsson P, Salzer J, Svenningsson A, Vrethem M, Olsson T, Piehl F, Frisell T (2020) Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurol 77:184\u2013191","journal-title":"JAMA Neurol"},{"issue":"6","key":"11389_CR33","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/BOR.0000000000000647","volume":"31","author":"R Mantegazza","year":"2019","unstructured":"Mantegazza R, Cavalcante P (2019) Diagnosis and treatment of myasthenia gravis. Curr Opin Rheumatol 31(6):623\u2013633","journal-title":"Curr Opin Rheumatol"},{"key":"11389_CR34","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","volume":"395","author":"P Mehta","year":"2020","unstructured":"Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ (2020) COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet (London, England) 395:1033\u20131034","journal-title":"Lancet (London, England)"},{"key":"11389_CR35","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s00415-016-8045-z","volume":"263","author":"N Melzer","year":"2016","unstructured":"Melzer N, Ruck T, Fuhr P, Gold R, Hohlfeld R, Marx A, Melms A, Tackenberg B, Schalke B, Schneider-Gold C, Zimprich F, Meuth SG, Wiendl H (2016) Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society. J Neurol 263:1473\u20131494","journal-title":"J Neurol"},{"key":"11389_CR36","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/S1474-4422(20)30413-0","volume":"19","author":"S Muppidi","year":"2020","unstructured":"Muppidi S, Guptill JT, Jacob S, Li Y, Farrugia ME, Guidon AC, Tavee JO, Kaminski H, Howard JF Jr, Cutter G, Wiendl H, Maas MB, Illa I, Mantegazza R, Murai H, Utsugisawa K, Nowak RJ (2020) COVID-19-associated risks and effects in myasthenia gravis (CARE-MG). Lancet Neurol 19:970\u2013971","journal-title":"Lancet Neurol"},{"key":"11389_CR37","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12974-022-02448-4","volume":"19","author":"C Nelke","year":"2022","unstructured":"Nelke C, Stascheit F, Eckert C, Pawlitzki M, Schroeter CB, Huntemann N, Mergenthaler P, Arat E, \u00d6zt\u00fcrk M, Foell D, Schreiber S, Vielhaber S, Gassa A, Stetefeld H, Schroeter M, Berger B, Totzeck A, Hagenacker T, Meuth SG, Meisel A, Wiendl H, Ruck T (2022) Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients. J Neuroinflamm 19:89","journal-title":"J Neuroinflamm"},{"key":"11389_CR38","doi-asserted-by":"crossref","first-page":"e299","DOI":"10.1212\/WNL.0000000000008688","volume":"94","author":"B Neumann","year":"2020","unstructured":"Neumann B, Angstwurm K, Mergenthaler P, Kohler S, Schonenberger S, Bosel J, Neumann U, Vidal A, Huttner HB, Gerner ST, Thieme A, Steinbrecher A, Dunkel J, Roth C, Schneider H, Schimmel E, Fuhrer H, Fahrendorf C, Alberty A, Zinke J, Meisel A, Dohmen C, Stetefeld HR (2020) Myasthenic crisis demanding mechanical ventilation: a multicenter analysis of 250 cases. Neurology 94:e299\u2013e313","journal-title":"Neurology"},{"key":"11389_CR39","doi-asserted-by":"crossref","first-page":"e299","DOI":"10.1212\/WNL.0000000000008688","volume":"94","author":"B Neumann","year":"2020","unstructured":"Neumann B, Angstwurm K, Mergenthaler P, Kohler S, Sch\u00f6nenberger S, B\u00f6sel J, Neumann U, Vidal A, Huttner HB, Gerner ST, Thieme A, Steinbrecher A, Dunkel J, Roth C, Schneider H, Schimmel E, Fuhrer H, Fahrendorf C, Alberty A, Zinke J, Meisel A, Dohmen C, Stetefeld HR (2020) Myasthenic crisis demanding mechanical ventilation: a multicenter analysis of 250 cases. Neurology 94:e299\u2013e313","journal-title":"Neurology"},{"key":"11389_CR40","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.semarthrit.2021.08.010","volume":"51","author":"R Raiker","year":"2021","unstructured":"Raiker R, DeYoung C, Pakhchanian H, Ahmed S, Kavadichanda C, Gupta L, Karde\u015f S (2021) Outcomes of COVID-19 in patients with rheumatoid arthritis: a multicenter research network study in the United States. Semin Arthritis Rheum 51:1057\u20131066","journal-title":"Semin Arthritis Rheum"},{"key":"11389_CR41","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa2030340","volume":"384","author":"C Salama","year":"2021","unstructured":"Salama C, Han J, Yau L, Reiss WG, Kramer B, Neidhart JD, Criner GJ, Kaplan-Lewis E, Baden R, Pandit L, Cameron ML, Garcia-Diaz J, Ch\u00e1vez V, Mekebeb-Reuter M, Lima de Menezes F, Shah R, Gonz\u00e1lez-Lara MF, Assman B, Freedman J, Mohan SV (2021) Tocilizumab in patients hospitalized with COVID-19 pneumonia. N Engl J Med 384:20\u201330","journal-title":"N Engl J Med"},{"key":"11389_CR42","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103358","volume":"57","author":"I Schiavetti","year":"2022","unstructured":"Schiavetti I, Ponzano M, Signori A, Bovis F, Carmisciano L, Sormani MP (2022) Severe outcomes of COVID-19 among patients with multiple sclerosis under anti-CD-20 therapies: a systematic review and meta-analysis. Mult Scler Relat Disord 57:103358","journal-title":"Mult Scler Relat Disord"},{"issue":"5","key":"11389_CR43","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1136\/annrheumdis-2020-218075","volume":"80","author":"H Schulze-Koops","year":"2020","unstructured":"Schulze-Koops H, Krueger K, Vallbracht I, Hasseli R, Skapenko A (2020) Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab. Ann Rheum Dis 80(5):e67. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218075","journal-title":"Ann Rheum Dis"},{"key":"11389_CR44","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102800","volume":"50","author":"M Sharifian-Dorche","year":"2021","unstructured":"Sharifian-Dorche M, Sahraian MA, Fadda G, Osherov M, Sharifian-Dorche A, Karaminia M, Saveriano AW, La Piana R, Antel JP, Giacomini PS (2021) COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: a systematic review. Mult Scler Relat Disord 50:102800","journal-title":"Mult Scler Relat Disord"},{"key":"11389_CR45","volume":"374","author":"RA Siemieniuk","year":"2021","unstructured":"Siemieniuk RA, Bartoszko JJ, D\u00edaz Martinez JP, Kum E, Qasim A, Zeraatkar D, Izcovich A, Mangala S, Ge L, Han MA, Agoritsas T, Arnold D, \u00c1vila C, Chu DK, Couban R, Cusano E, Darzi AJ, Devji T, Foroutan F, Ghadimi M, Khamis A, Lamontagne F, Loeb M, Miroshnychenko A, Motaghi S, Murthy S, Mustafa RA, Rada G, Rochwerg B, Switzer C, Vandvik PO, Vernooij RW, Wang Y, Yao L, Guyatt GH, Brignardello-Petersen R (2021) Antibody and cellular therapies for treatment of COVID-19: a living systematic review and network meta-analysis. BMJ 374:n2231","journal-title":"BMJ"},{"key":"11389_CR46","doi-asserted-by":"crossref","first-page":"e2109","DOI":"10.1212\/WNL.0000000000011669","volume":"96","author":"G Sol\u00e9","year":"2021","unstructured":"Sol\u00e9 G, Mathis S, Friedman D, Salort-Campana E, Tard C, Bouhour F, Magot A, Annane D, Clair B, Le Masson G, Soulages A, Duval F, Carla L, Violleau MH, Saulnier T, Segovia-Kueny S, Kern L, Antoine JC, Beaudonnet G, Audic F, Kremer L, Chanson JB, Nadaj-Pakleza A, Stojkovic T, Cintas P, Spinazzi M, Foubert-Samier A, Attarian S (2021) Impact of coronavirus disease 2019 in a French cohort of myasthenia gravis. Neurology 96:e2109\u2013e2120","journal-title":"Neurology"},{"key":"11389_CR47","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/ana.26028","volume":"89","author":"MP Sormani","year":"2021","unstructured":"Sormani MP, De Rossi N, Schiavetti I, Carmisciano L, Cordioli C, Moiola L, Radaelli M, Immovilli P, Capobianco M, Trojano M, Zaratin P, Tedeschi G, Comi G, Battaglia MA, Patti F, Salvetti M (2021) Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis. Ann Neurol 89:780\u2013789","journal-title":"Ann Neurol"},{"key":"11389_CR48","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1001\/jama.2020.17023","volume":"324","author":"JAC Sterne","year":"2020","unstructured":"Sterne JAC, Murthy S, Diaz JV, Slutsky AS, Villar J, Angus DC, Annane D, Azevedo LCP, Berwanger O, Cavalcanti AB, Dequin PF, Du B, Emberson J, Fisher D, Giraudeau B, Gordon AC, Granholm A, Green C, Haynes R, Heming N, Higgins JPT, Horby P, J\u00fcni P, Landray MJ, Le Gouge A, Leclerc M, Lim WS, Machado FR, McArthur C, Meziani F, M\u00f8ller MH, Perner A, Petersen MW, Savovic J, Tomazini B, Veiga VC, Webb S, Marshall JC (2020) Association between administration of systemic corticosteroids and mortality among critically Ill patients with COVID-19: a meta-analysis. JAMA 324:1330\u20131341","journal-title":"JAMA"},{"key":"11389_CR49","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1136\/annrheumdis-2020-219498","volume":"80","author":"A Strangfeld","year":"2021","unstructured":"Strangfeld A, Sch\u00e4fer M, Gianfrancesco MA, Lawson-Tovey S, Liew JW, Ljung L, Mateus EF, Richez C, Santos MJ, Schmajuk G, Scir\u00e8 CA, Sirotich E, Sparks JA, Sufka P, Thomas T, Trupin L, Wallace ZS, Al-Adely S, Bachiller-Corral J, Bhana S, Cacoub P, Carmona L, Costello R, Costello W, Gossec L, Grainger R, Hachulla E, Hasseli R, Hausmann JS, Hyrich KL, Izadi Z, Jacobsohn L, Katz P, Kearsley-Fleet L, Robinson PC, Yazdany J, Machado PM (2021) Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 80:930\u2013942","journal-title":"Ann Rheum Dis"},{"key":"11389_CR50","unstructured":"Team RC (2021) R: A language and environment for statistical computing. In, https:\/\/www.R-project.org\/"},{"key":"11389_CR51","doi-asserted-by":"crossref","first-page":"620","DOI":"10.3906\/sag-2004-168","volume":"50","author":"A Tufan","year":"2020","unstructured":"Tufan A, Avano\u011flu G\u00fcler A, Matucci-Cerinic M (2020) COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs. Turk J Med Sci 50:620\u2013632","journal-title":"Turk J Med Sci"},{"key":"11389_CR52","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/cei.13546","volume":"203","author":"A Uzawa","year":"2020","unstructured":"Uzawa A, Kuwabara S, Suzuki S, Imai T, Murai H, Ozawa Y, Yasuda M, Nagane Y, Utsugisawa K (2020) Roles of cytokines and T cells in the pathogenesis of myasthenia gravis. Clin Exp Immunol 203:366\u2013374","journal-title":"Clin Exp Immunol"},{"key":"11389_CR53","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1001\/jamainternmed.2020.0994","volume":"180","author":"C Wu","year":"2020","unstructured":"Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C, Zhang Y, Song J, Wang S, Chao Y, Yang Z, Xu J, Zhou X, Chen D, Xiong W, Xu L, Zhou F, Jiang J, Bai C, Zheng J, Song Y (2020) Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 180:934\u2013943","journal-title":"JAMA Intern Med"},{"key":"11389_CR54","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/mus.25973","volume":"57","author":"JS Yi","year":"2018","unstructured":"Yi JS, Guptill JT, Stathopoulos P, Nowak RJ, O\u2019Connor KC (2018) B cells in the pathophysiology of myasthenia gravis. Muscle Nerve 57:172\u2013184","journal-title":"Muscle Nerve"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-022-11389-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-022-11389-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-022-11389-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T17:21:26Z","timestamp":1672852886000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-022-11389-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,27]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["11389"],"URL":"https:\/\/doi.org\/10.1007\/s00415-022-11389-0","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,27]]},"assertion":[{"value":"27 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"F. Stascheit received speaker honoraria from Alexion. U. Grittner reports no conflict of interest, S. Hoffmann received speaker honoraria from Alexion. P. Mergenthaler receives funding from the Einstein Foundation Berlin, and is supported by grants from the Bundesministerium f\u00fcr Bildung und Forschung, the Volkswagen Foundation, and the Else Kr\u00f6ner Fresenius Stiftung, and is on the board of HealthNextGen Inc. and has equity interest in the company. M. Schroeter reports speaker honoraria from Argenx, Bayer, Biogen, Datamed, Grifols, Merck, Roche, Sanofi. He received consulting fees from Alexion, Biogen, Argenx\/Efran MG, Gilead, and Roche. T. Ruck reports grants from German Ministry of Education, Science, Research and Technology, grants and personal fees from Sanofi-Genzyme, Novartis and Alexion; personal fees from Abbott, argenx, Biogen, Bristol-Myers Squibb, Roche and Teva; personal fees and nonfinancial support from Merck Serono, outside the submitted work. F. Blaes received speaker honoraria from UCB, Argenx, Alexion and Grifols. J. Kaiser reports no conflicts of interests. U. Schara received speaker honoria from Alexion and Biogen. A. D. Marina reports no conflicts of interests. A. Thieme reports no conflicts of interests. T. Hagenacker reports speaker honoraria from Alexion, argenx and Hormosan, Biogen, Roche Sanofi Genzyme and Novartis Gene Therapies. He received consulting fees from Biogen, Roche, Sanofi Genzyme, Alexion, argenx, Hormsosan and Alnylam and research support from Sanofi Genzyme, Roche, Biogen and Novartis. C. Jacobi reports speaker honoraria from Alexion, CSL Behring, TEVA and Sanofi Genzyme. He received consulting fees from Alexion, Roche, Merck Serono and Novartis. P. P. Urban received speaker honoraria from Alexion. B. Berger received travel grants and\/or training expenses from Bayer Vital GmbH, Ipsen Pharma GmbH, Norvartis, Biogen GmbH and Genzyme, as well as lecture fees from Ipsen Pharma GmbH, Alexion Pharma GmbH, Merck, Sanofi Genzyme and Roche. K. C. Knop received speaker honoraria from Alexion, Bayer, Biogen, Grifols, Hormosan, Novartis, Sanofi Genzyme, Roche and consulting fees from Hormosan, Merck, Sanofi Genzyme and Sarepta. B. Schalke received consulting fees from argnx. D.J. Lee received speaking honoria from Alexion, Anylam, Biogen, Janssen, Merck, Novartis, Roche and Sanofi. P. Kalischewski received speaker honoraria, consulting fees and NIS from\u00a0Biogen, Sanofi, Teva, Merck, Roche, Novartis and Biogen. M. Pawlitzki received speaker honoraria and travel\/accommodation\/meeting expenses from Novartis. H. Wiendl is acting as a paid consultant for Abbvie, Actelion, Biogen, IGES, Johnson & Johnson, Novartis, Roche, Sanofi-Aventis, and the Swiss Multiple Sclerosis Society. His research is funded by the German Ministry for Education and Research (BMBF), Deutsche Forschungsgemeinschaft (DFG), Else Kr\u00f6ner Fresenius Foundation, Fresenius Foundation, the European Union, Hertie Foundation, NRW Ministry of Education and Research, Interdisciplinary Center for Clinical Studies (IZKF) Muenster and RE Children\u2019s Foundation, Biogen, GlaxoSmithKline GmbH, Roche Pharma AG, Sanofi-Genzyme. A. Meisel received speaker honoraria, consulting fees or financial research support from Alexion, argnx, Grifols, Hormosan, Janssen, Octapharmam UCB and Vitaccess for consulting services and financial research support from Octapharma and Alexion. He serves as chairman of the medical advisory board of the German Myasthenia Gravis Society.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The study was conducted in accordance to the Declaration of Helsinki and the STROBE reporting guidelines and was registered at the WHO-licensed German clinical trial registry (DRKS00024099). The study was approved by the ethics committee of the Charit\u00e9-Universit\u00e4tsmedizin Berlin (EA1\/025\/11).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors have approved the manuscript for submission; accordingly, the manuscript conforms to the journal\u2019s policies. The authors take full responsibility for the data, the analyses and interpretation, and the conduct of the research. They have full access to all data, and the right to publish any and all data separate and apart from the guidance of any sponsor.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}